Boston, MA 02/06/2014 (wallstreetpr) – Pfizer Inc. (NYSE:PFE) has been carrying out trials on its latest breast cancer drug, called palbociclib. It has been carrying out this trial for a very long time, in the hope that the success of this breast cancer drug will help improve its performance in the financial market. The latest results indicate that the company may have been right after all. Breast cancer patients show remarkable improvement and are not as sickly as they were prior to using this drug from Pfizer Inc. More than that is the fact that these patients are not experiencing worsening in their condition after using the drug.
The drug was not tried on patients singularly. It was tried on patients in combination with letrozole, which is a hormonal therapy. The results were then compared with those of breast cancer patients who were only on letrozole. Moreover, it is also good to mention that the drug was tested on post-menopausal breast cancer patients. Thus far, everything seems to be going on well. Breast cancer remains one of the most common diseases across the entire globe. It affects both men and women, though the number of the latter is much higher than the former.
Every year close to 232,000 new female breast cancer patients are reported in the US alone. This is in comparison to around 2,240 male patients affected by breast cancer. Breast cancer is also a fatal disease, with the US reporting 39,000 female deaths every year. Similarly, in the US, close to 410 male patients die due to breast cancer. If the new breast cancer drug by Pfizer Inc. (NYSE:PFE) proves efficient in reducing the influence and impact of this disease, it will have made a massive difference, and brought hope to people who would otherwise have had none.
The new drug will be available not only in the US, but also in all countries around the world. Breast cancer patients will have the chance to use this new Pfizer Inc. (NYSE:PFE) drug and see how much it will reduce the ill effects of this disease on their bodies. Treating breast cancer, just as it is the case with all other types of cancer, is not cheap. It is expensive, and requires too much time. In the US alone, there are close to 2.6 million women living with breast cancer, and some are in different stages of treatment, while others have no hope of getting a remedy for this disease.
Survival rate for people suffering from breast cancer differs depending on a number of factors. On the other hand, the new drug will contribute greatly to increasing the survival rate and give hope to people living with breast cancer. Since 1975, the survival rate has been on an upward trend, from a low of 75.2%, to around 90.5 percent reported in 2005. Pfizer Inc. (NYSE:PFE) is involved in producing drugs that cater for different types of diseases, and not just one. It is a global brand, with years of experience in health care, and this latest innovation, will enhance its reputation.
